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conventional open lobectomy for patients with non-small-cell
lung cancer (NSCLC), to stratify potential differences in long-term
survival outcomes.
Methods: We established a multi-institutional registry for 4138
patients with NSCLC who underwent lobectomy between January,
2000, and December, 2007, from eight institutions in China. Age,
gender, histological type, and tumour staging, based on the latest
TNM classification, were entered into a non-parsimonious multi-
variable logistic-regression model. The predicted probability
derived from the logistic equation was used as the propensity
score for each individual. Based on similar propensity scores,
we matched 1356 of the 1584 patients who underwent VATS
lobectomy with 1356 of the 2554 patients who underwent open
lobectomy, and compared their long-term survival outcomes.
Findings: The mean age of the 2712 matched patients was 59
years (SD 11). After propensity matching, VATS and open lobec-
tomy were similar with regard to important prognostic variables.
In multivariate analysis, four prognostic factors were indepen-
dently associated with improved survival: gender (p = 0.001), his-
tological type (p < 0.001), pathological staging (p < 0.001), and
surgery type (lobectomy/sleeve resection vs. pneumonectomy
(p = 0.044). Patients who underwent VATS versus open lobectomy
had similar long-term survival (p = 0.101).
Interpretation: The current propensity-score analysis suggests
that well-matched patients with NSCLC who underwent VATS
lobectomy did not have inferior long-term survival outcomes
compared with those who underwent open lobectomy.
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Background: We investigated the significance of CD24 and CD44
expression for predicting response to chemotherapy, and progno-
sis, in patients with primary breast cancer.
Methods: Diagnosis of breast cancer was confirmed by core-
needle biopsy, and immunohistochemical studies were
performed. Preoperatively, patients received anthracycline-con-
taining chemotherapy. Expression of CD44 and CD24 was
assessed immunohistochemically and the association with che-
motherapy response and prognosis was analysed.
Findings: 139 women were enrolled in this study between 2001
and 2004. In correlation analysis, CD24 expression was negatively
associated with pathological response to chemotherapy
(p = 0.0003). A machine learning technique with an alternating
decision tree showed that four logical rules are involved in pre-
dicting response, depending on the combination of CD24, HER2,
tumour stage, CD44, progesterone receptor, and patient age. In
survival analysis, patients who were CD44 (++) showed a signifi-
cantly favourable prognosis compared with others (p = 0.0002).
Multivariate analysis showed that CD44 expression had an inde-
pendent prognostic value (p < 0.001).
Interpretation: We found a significant correlation between CD44
expression and prognosis, and between CD24 expression and
response to chemotherapy. CD24 and CD44 expression could be
useful predictive markers, although further studies are needed.
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Introduction: The American Cancer Society estimated 70,980
new cases of bladder cancer in the USA during 2009, with
approximately 14,330 bladder-cancer-related deaths during the
same period. Cystoscopy, the gold standard diagnostic evaluation
for detection of bladder cancer and surveillance after therapy, is
invasive, expensive, and unpopular among patients. Urine
cytology, as an adjunct to cystoscopy, is less sensitive for low-
grade tumours. This study evaluated the clinical significance of
survivin (an inhibitor of apoptosis) mRNA expression in diagnosis
of transitional-cell carcinoma (TCC) in patients with bladder
cancer.
Methods: Quantitative detection of survivin mRNA expression
was evaluated in exfoliated cells in urine, by use of real-time
quantitative (qRT)-PCR, in 135 patients with suspicion of new or
recurrent bladder cancer, prior to transurethral resection. Of 135
cases, 98 were histologically proven TCC, whereas 37 had other,
benign urological diseases. Fifteen healthy volunteers were also
included, as well as 62 patients with treated superficial bladder
cancer who had a current negative biopsy and were receiving fol-
low-up care.
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Findings: Urine survivin expression detected bladder can-
cer with higher sensitivity (85.25%, 95% CI 73.8–93.0%) and speci-
ficity (100.00%, 90.4–100.0%) than urine cytology, which showed
52.29% sensitivity (42.5–61.9%) and 87.88% specificity (77.5–
94.6%). In the 62 treated patients, urine survivin expression had
22.92% sensitivity (12.0–37.3%) and 92.86% specificity (66.1–
98.8%) for detecting bladder cancer. Surprisingly, among the 62
treated patients, 13 (21%) showed survivin expression. Follow-
up of these patients for 1 year revealed recurrence of TCC in nine
patients (69%).
Interpretation: This study shows the clinical utility of survi-
vin expression in new or recurrent bladder cancer, and in patients
with a negative biopsy receiving follow-up care. Thus, highly
sensitive and specific determination of survivin in exfoliated cells
in urine, by use of qRT-PCR, seems to provide a simple,
non-invasive diagnostic biomarker for routine screening of blad-
der cancer.
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Background: The role of F-18 FDG-PET/CT in gastric cancer is
limited in some cases by gastric histology. This retrospective
study was designed to assess the accuracy of F-18 FDG-PET/CT
for imaging stomach cancer, and its correlation with other
clinicopathological findings, including its role as a prognostic
factor.
Methods: 431 patients who underwent F-18 FDG-PET/CT before
surgery for gastric cancer were included in this study, from
December, 2006, to May, 2010. The mean age was 62 years (SD
11.6) and the male-to-female ratio was 265:167. Patients were
divided into three groups according to the maximal standardised
uptake value (SUVmax) of the tumour. All patients medical
records were reviewed, including surgical and pathological
results. All parameters were compared by one-way ANOVA and
v2-test. Survival curves were calculated using the Kaplan–Meier
method, and the statistical difference in prognosis was analysed
using a generalised log-rank test.
Findings The mean tumour SUVmax was 6.51 in surgically
treated stomach cancer. Group 1 included 175 patients with SUV-
max of 0, group 2 was 124 patients with SUVmax lower than 5,
and group 3 was 133 patients with SUVmaxP 5. The intensity
of FDG uptake correlated with tumour size (r2 = 0.103, p < 0.001),
and showed significant difference according to TNM
stage, tumour grade, lymphovascular invasion, nerve invasion,
and sex. SUVmax was higher in poorly differentiated tumours
and in men. Apart from SUVmax, all of the pathological parame-
ters, including TNM stage, tumour grade, lymphovascular inva-
sion, and nerve invasion, were not associated with median
survival.
Interpretation: The SUVmax of F-18 FDG-PET/CT of surgically
treated gastric cancer correlated with TNM stage, tumour grade,
lymphovascular invasion, nerve invasion, and sex. SUVmax also
correlated with median survival.
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Background: According to the Malaysian National Cancer Regis-
try, nasopharyngeal carcinoma (NPC) was the third most common
cancer among men in peninsular Malaysia in 2006. Variations in
specific DNA repair genes alter individual cancer risk, and the
DNA repair system has a crucial role in maintaining the integrity
of the human genome. Xeroderma pigmentosum complementa-
tion group D (XPD)/excision repair cross-complementing group 2
(ERCC2) encodes a helicase that participates in nucleotide excision
repair. This variant allele of polymorphism XPD Lys751Gln has
been associated with increased DNA adduct levels, and with low
DNArepair capacity.Another gene, theX-ray cross complementing
group 1 (XRCC1) encodes a protein involved in the base-excision
repair pathway. Arg280His is located in the nuclear antigen-bind-
ing region of proliferating cells. Reports suggest that an Arg280His
variant protein is defective in localisation of damaged sites in the
chromosome, thereby reducing the efficiency of base excision
repair. In this study, we investigated the possible association of
these two polymorphisms with an increased risk of developing
NPC in the Malaysian population.
Methods: A molecular epidemiological study was done using a
hospital-based case-control study design. A total of 113 cases and
130 controls were available for study, matched for age, sex, and
ethnicity. Single nucleotide polymorphism (SNP) genotyping was
carried out using a PCR-restriction fragment length polymor-
phism (RFLP) method.
Findings: A total of 113 cases and 130 controls were analysed.
The frequency of the XPD codon 751 homozygous wild-type Lys/
Lys genotype was 87.6% (99/113) in cases and 73.9% (96/130) in
controls; the heterozygous Lys/Gln genotype was 12.4% (14/113)
in cases and 25.4% (33/130) in controls; and the Gln/Gln genotype
was 0% (0/113) in cases and 0.7% (1/130) in controls. For XPD/
ERCC2 codon 751, an odds ratio (OR) of 2.41 was observed (95%
CI 1.17– 4.97, p = 0.017). Risk of NPC was nearly two and a half
times higher for individuals with the homozygous wild-type
Lys/Lys grenotype than for the heterozygous Lys/Gln genotype,
adjusted for age, sex, and ethnicity. To our knowledge, there have
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